SAN CARLOS, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Tuesday reported a loss of $40.5 million in its fourth quarter.
The San Carlos, California-based company said it had a loss of 58 cents per share.
The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share.
The biopharmaceutical company posted revenue of $2.3 million in the period, which also fell short of Street forecasts. Six analysts surveyed by Zacks expected $3.5 million.
For the year, the company reported that its loss widened to $131.8 million, or $1.89 per share. Revenue was reported as $32.2 million.
ChemoCentryx shares have dropped 19% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $29.46, a decline of 57% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI
Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News